A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Itraconazole; Ritonavir
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 27 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 New trial record